Takeda's arcotatug tavatecan meets dual primary endpoints in Phase 3 gastric cancer study

Takeda announced results from its Phase 3 G-HOPE-001 study of arcotatug tavatecan in advanced gastric or gastroesophageal junction adenocarcinoma. The drug met dual primary endpoints: median overall survival of 10.2 vs 6.9 months with standard treatment (HR 0.57, p<0.0001) and progression-free survival of 7.1 vs 3.1 months.

Detected & updated continuously · Source: Nebula